SecSonar.com

Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Alnylam Pharmaceuticals, Inc. (ALNY) is a Biotechnology company based in US with a market capitalization of $40.3B. Revenue grew 65.2% year-over-year and the company generated $465.4M in free cash flow. This page tracks ALNY's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 2.23K employees · IPO Jun 1, 2004

Valuation

Valuation & price

$286.98 · as of May 17, 2026 · -41.6% vs 52w high

123.2

P/E ratio

Latest-FY diluted EPS

51.01

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$482$382$283Jul 25Dec 25Jul 26Jul 7, 25$324.13Jul 9, 25$320.87Jul 11, 25$314.94Jul 15, 25$311.12Jul 17, 25$324.69Jul 21, 25$320.52Jul 23, 25$325.64Jul 25, 25$328.81Jul 29, 25$330.55Jul 31, 25$392.24Aug 4, 25$419.56Aug 6, 25$428.14Aug 11, 25$435.00Aug 13, 25$432.52Aug 15, 25$448.91Aug 19, 25$458.28Aug 21, 25$467.55Aug 25, 25$443.64Aug 27, 25$454.18Aug 29, 25$446.51Sep 3, 25$447.43Sep 5, 25$452.00Sep 9, 25$482.13Sep 11, 25$468.58Sep 16, 25$461.24Sep 18, 25$452.17Sep 22, 25$458.92Sep 24, 25$458.37Sep 26, 25$446.40Sep 30, 25$456.00Oct 2, 25$460.99Oct 6, 25$452.00Oct 8, 25$450.68Oct 10, 25$460.46Oct 14, 25$469.36Oct 16, 25$481.07Oct 21, 25$474.00Oct 23, 25$464.00Oct 27, 25$478.58Oct 29, 25$481.59Oct 31, 25$456.04Nov 4, 25$423.47Nov 6, 25$440.49Nov 10, 25$441.70Nov 12, 25$452.74Nov 14, 25$449.16Nov 18, 25$462.30Nov 20, 25$445.79Nov 25, 25$429.80Nov 28, 25$451.23Dec 2, 25$464.93Dec 4, 25$465.34Dec 8, 25$430.02Dec 10, 25$404.46Dec 12, 25$397.55Dec 16, 25$391.17Dec 18, 25$396.04Dec 22, 25$407.73Dec 24, 25$400.69Dec 29, 25$398.82Jan 2, 26$400.17Jan 6, 26$406.40Jan 8, 26$399.40Jan 12, 26$370.91Jan 14, 26$366.86Jan 16, 26$359.27Jan 21, 26$365.46Jan 23, 26$357.98Jan 27, 26$354.75Jan 29, 26$346.79Feb 2, 26$339.11Feb 4, 26$351.96Feb 9, 26$320.00Feb 11, 26$322.28Feb 13, 26$314.40Feb 18, 26$332.68Feb 20, 26$336.19Feb 24, 26$332.85Feb 26, 26$331.24Mar 2, 26$325.07Mar 4, 26$327.30Mar 6, 26$320.66Mar 10, 26$322.38Mar 12, 26$317.23Mar 17, 26$320.42Mar 19, 26$311.10Mar 23, 26$306.66Mar 25, 26$328.70Mar 27, 26$317.36Mar 31, 26$330.87Apr 2, 26$318.85Apr 7, 26$319.52Apr 9, 26$321.28Apr 13, 26$333.00Apr 15, 26$333.39Apr 17, 26$309.66Apr 22, 26$310.58Apr 24, 26$305.54Apr 28, 26$302.11Apr 30, 26$309.49May 4, 26$297.93May 6, 26$303.00May 8, 26$295.05May 12, 26$292.03May 14, 26$293.45May 18, 26$286.27May 20, 26$298.48May 22, 26$297.45May 28, 26$305.06Jun 1, 26$295.63Jun 3, 26$292.58Jun 5, 26$303.05Jun 9, 26$297.69Jun 11, 26$289.39Jun 15, 26$287.80Jun 17, 26$282.72Jun 22, 26$286.41Jun 24, 26$294.06Jun 26, 26$291.37Jul 2, 26$312.78
$278.0952-week range$491.22
Loading valuation history…

Fundamentals

Key fundamentals

$40.3B

Market cap

65.2%

Revenue growth (YoY)

81.8%

Gross margin

$465.4M

Free cash flow (USD)

-$1.6B

Net debt

Net cash position

2.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$47.2MFY 2017$89.9MFY 2018$74.9MFY 2019$219.8MFY 2020$492.9MFY 2021$844.3MFY 2022$1.0BFY 2023$1.8BFY 2024$2.2BFY 2025$3.7B
$47.2M$3.7B

Free cash flow by year

2016 → 2025

FY 2016$-372.3MFY 2017$-487.0MFY 2018$-689.5MFY 2019$-418.6MFY 2020$-685.3MFY 2021$-718.1MFY 2022$-613.3MFY 2023$41.9MFY 2024$-42.6MFY 2025$465.4M
-$372.3M$465.4M

Gross margin by year

2021 → 2025

FY 202183.4%FY 202283.7%FY 202383.0%FY 202485.6%FY 202581.8%
83.4%81.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.1M · 10b5-1 PlanPYOTT DAVID E I · Director · $1.1MJun 3, 2026Filing
  • 8-K eventDirector AppointmentMay 27, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • Quarterly report10-Q FiledApr 30, 2026Filing
  • Insider sellInsider Sell $1.3M · 10b5-1 PlanMcLaughlin Melissa · Chief Human Resources Officer · $1.3MApr 7, 2026Filing

Questions

Frequently asked questions

What is Alnylam Pharmaceuticals, Inc.'s market cap?

Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalization of $40.3B.

What is ALNY's P/E ratio?

ALNY trades at a price-to-earnings ratio of 123.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is ALNY's price-to-book (P/B) ratio?

ALNY trades at 51.01 times book value per share.

Are insiders buying ALNY stock?

SEC Form 4 filings show no open-market insider buys at Alnylam Pharmaceuticals, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

RVMD

Revolution Medicines, Inc.

$33.3B

ARGX

argenx SE

$51.7B

RPRX

Royalty Pharma plc

$23.6B

UTHR

United Therapeutics Corporation

$23.4B

INSM

Insmed Incorporated

$23.3B

ROIV

Roivant Sciences Ltd.

$21.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.